07:00 , Aug 11, 2014 |  BioCentury  |  Strategy

Profusion of exclusions

Express Scripts Holding Co.'s 2015 formulary exclusions offer hope that companies can renegotiate once-excluded drugs back into coverage. But the pharmacy benefits manager appears to be expanding the number of drugs and drug classes it...
07:00 , Sep 2, 2013 |  BC Week In Review  |  Company News

Acton Pharmaceuticals, Meda deal

Meda will acquire Acton for $135 million in cash plus a $10 million near-term undisclosed development milestone. Acton is also eligible for sales-based milestones, which the company said may bring the total deal value up...
07:00 , Sep 2, 2013 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones Allenex AB (SSE:ALNX) gained SEK1.03 (48%) to SEK3.19 on Thursday after saying Mexico approved XM-ONE to detect human leukocyte antigen (HLA) and non-HLA antibodies between donor and recipient in organ transplantations. XM-ONE is an endothelial...
23:58 , Aug 30, 2013 |  BC Extra  |  Company News

Meda to acquire asthma play Acton

Meda AB (SSE:MEDA) will acquire asthma play Acton Pharmaceuticals Inc. (Marlborough, Mass.) for $135 million in cash plus a $10 million undisclosed near-term development milestone. Acton is also eligible for sales-based milestones that the company...
07:00 , Sep 24, 2012 |  BC Week In Review  |  Clinical News

Aerospan flunisolide HFA regulatory update

FDA approved an sNDA from Acton for Aerospan flunisolide HFA as maintenance treatment of asthma in patients >=6 years of age. Acton plans to launch the hydrofluoroalkane (HFA)-propelled inhaled formulation of flunisolide in the U.S....
08:00 , Nov 8, 2010 |  BC Week In Review  |  Clinical News

Aerospan flunisolide HFA regulatory update

Acton submitted an sNDA to FDA for Aerospan flunisolide HFA to include manufacturing information and data to support a commercial launch. Acton said the PDUFA date is March 3, 2011, and anticipates a launch in...
08:00 , Jan 11, 2010 |  BC Week In Review  |  Company News

Acton, Forest Laboratories sales and marketing update

Acton received exclusive, worldwide rights to develop and commercialize Forest's Aerospan flunisolide. Forest will receive an undisclosed upfront payment and is eligible for milestones and royalties. The hydrofluoroalkane (HFA) formulated inhaled corticosteroid was approved in...
08:00 , Jan 11, 2010 |  BioCentury  |  Finance

Harvesting from Forest

A pair of former Forest Laboratories Inc. alumni have founded specialty respiratory company Acton Pharmaceuticals Inc. around Aerospan flunisolide, a product they in-licensed from Forest (NYSE: FRX). FDA approved Aerospan to treat asthma in 2006, but...
03:17 , Jan 7, 2010 |  BC Extra  |  Financial News

Acton raises $15 million

Acton Pharmaceuticals Inc. (Marlborough, Mass.) raised $15 million in a series A round led by Sequoia Capital. Acton also licensed exclusive, worldwide rights to Aerospan flunisolide from Forest Laboratories Inc. (NYSE:FRX). FDA approved the hydrofluoroalkane...
08:00 , Feb 6, 2006 |  BC Week In Review  |  Clinical News

Aerospan flunisolide regulatory update

FDA approved an NDA for Aerospan flunisolide as maintenance treatment of asthma as prophylactic therapy in patients 6 years of age and older. Aerospan is a hydrofluoroalkane (HFA) formulated inhaled corticosteroid. Forest Laboratories Inc. (FRX),...